Literature DB >> 16797726

Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.

Sophie Sibéril1, Charles-Antoine Dutertre, Charlotte Boix, Emmanuelle Bonnin, Renée Ménez, Enrico Stura, Sylvie Jorieux, Wolf-Herman Fridman, Jean-Luc Teillaud.   

Abstract

The binding of IgG antibodies to receptors for the Fc region of IgG (FcgammaR) is a critical step for the initiation and/or the control of effector immune functions once immune complexes have been formed. Site-directed and random mutagenesis as well as domain-swapping, NMR and X-ray cristallography have made it possible to get detailed insights in the molecular mechanisms that govern IgG/FcgammaR interactions and to define some of the structural determinants that impact IgG binding to the various FcgammaR. It has demonstrated the role of particular stretches and individual residues located in the lower hinge region of the CH2 domain and in the CH2 and CH3 domains of the Fc region. The importance of the sugar components linked to asparagine 297 in the binding properties of IgG1, the human IgG isotype the most widely used in antibody-based therapies, has been also highlighted. These data have led to the engineering of a new generation of monoclonal antibodies for therapeutic use with optimized effector functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797726     DOI: 10.1016/j.imlet.2006.05.009

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  18 in total

Review 1.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 2.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 3.  Involvement of Fc receptors in disorders of the central nervous system.

Authors:  Eitan Okun; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2009-10-21       Impact factor: 3.843

4.  An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.

Authors:  Abdolkarim Sheikhi; Mohammad Hojjat-Farsangi
Journal:  Hum Vaccin Immunother       Date:  2020-07-14       Impact factor: 3.452

5.  Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.

Authors:  Jing Li; Changhua Zhou; Bin Dong; Hong Zhong; Siqi Chen; Qing Li; Zhong Wang
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

6.  A homogeneous bioluminescent immunoassay for parallel characterization of binding between a panel of antibodies and a family of Fcγ receptors.

Authors:  Nidhi Nath; Becky Godat; Rod Flemming; Marjeta Urh
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

7.  Diagnostic value of blood gene expression signatures in active tuberculosis in Thais: a pilot study.

Authors:  N Satproedprai; N Wichukchinda; S Suphankong; W Inunchot; T Kuntima; S Kumpeerasart; S Wattanapokayakit; S Nedsuwan; H Yanai; K Higuchi; N Harada; S Mahasirimongkol
Journal:  Genes Immun       Date:  2015-03-12       Impact factor: 2.676

Review 8.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

9.  Fc gamma receptor CD64 modulates the inhibitory activity of infliximab.

Authors:  Kacper A Wojtal; Gerhard Rogler; Michael Scharl; Luc Biedermann; Pascal Frei; Michael Fried; Achim Weber; Jyrki J Eloranta; Gerd A Kullak-Ublick; Stephan R Vavricka
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

10.  Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.

Authors:  Joel F G Cohen-Solal; Lydie Cassard; Emilie M Fournier; Shannon M Loncar; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Dermatol Res Pract       Date:  2010-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.